{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:11:48Z","timestamp":1761919908649,"version":"3.44.0"},"reference-count":18,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2014,11,10]]},"abstract":"<jats:p>Temozolomide, an oral alkylating agent, is used in the treatment of glioblastoma. We describe a case of a 62-year-old woman developing jaundice with significant derangement of liver function tests on day 17 of focal radiotherapy with concomitant temozolomide. There was no structural abnormality on imaging and liver biopsy was performed. Pathology revealed absence of small terminal bile ducts affecting up to 60% of sampled portal tracts and senescence of many of the remaining small bile ducts, in keeping with a diagnosis of acute vanishing bile duct syndrome. This is a rare syndrome. It has been documented in association with Hodgkin's lymphoma and viral causes. Drugs implicated as precipitating this condition include antiseizure medications, some antibiotics, ibuprofen and antifungals. Temozolomide was stopped. The patient received supportive care, ursodeoxycholic acid 750\u2005mg daily and cholestyramine 4 g twice daily. She was otherwise asymptomatic and her blood results returned to normal by day 129.<\/jats:p>","DOI":"10.1136\/bcr-2014-208117","type":"journal-article","created":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T13:33:46Z","timestamp":1417181626000},"page":"bcr2014208117","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma"],"prefix":"10.1136","volume":"2014","author":[{"given":"Matthew","family":"Mason","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oyedele","family":"Adeyi","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara-Ann","family":"Millar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,11,28]]},"reference":[{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2356"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.3","unstructured":"Health Canada. TEMODAL (temozolomide)\u2014risk of liver problems\u2014for health professionals. 07\/05\/2014 Health Canada, 2014."},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2493-9"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.5","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1177\/030089161309900426","article-title":"Vanishing bile duct syndrome as a manifestation of Hodgkin's lymphoma: a case report and review of the literature","volume":"99","author":"Nader","year":"2013","journal-title":"Tumori"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2012.01058.x"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.7","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005434015863"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.8","doi-asserted-by":"crossref","first-page":"pii: bcr0620114369","DOI":"10.1136\/bcr.06.2011.4369","article-title":"Vanishing bile duct syndrome in a HIV patient on HAART therapy","volume":"2011","author":"Gnanaraj","year":"2011","journal-title":"BMJ Case Rep"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.9","doi-asserted-by":"publisher","DOI":"10.1177\/0883073809343474"},{"issue":"(4 Pt 1)","key":"2025082804380553000_2014.nov28_1.bcr2014208117.10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/0016-5085(92)90780-3","article-title":"Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome","volume":"102","author":"Forbes","year":"1992","journal-title":"Gastroenterology"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.11","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31823c2500"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.12","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.9.953"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1742-7843.2009.00474.x","article-title":"Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man","volume":"106","author":"Juricic","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.14","first-page":"1626","article-title":"Vanishing bile duct syndrome temporally associated with ibuprofen use","volume":"91","author":"Alam","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.15","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200209000-00014"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2008.01291.x"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.17","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.3748\/wjg.v12.i22.3487","article-title":"Ursodeoxycholic acid treatment of vanishing bile duct syndromes","volume":"12","author":"Pusl","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025082804380553000_2014.nov28_1.bcr2014208117.18","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/MPG.0b013e3182a95951","article-title":"Nonsteroidal anti-inflammatory drug-induced vanishing bile duct syndrome treated with plasmapheresis","volume":"57","author":"Kawasaki","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2014-208117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:38:15Z","timestamp":1756381095000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2014-208117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,28]]},"references-count":18,"alternative-id":["10.1136\/bcr-2014-208117"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2014-208117","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2014,11,28]]}}}